Abstract:Abstract Background In the central nervous system, the myelin sheath and the cells that form it—oligodendrocytes—are associated with cognitive function. Oligodendrocyte abnormalities is an important early pathogenic factor of Alzheimer’s disease (AD). However, it is unclear how the hippocampal oligodendrocytes change during early AD and whether early hippocampal oligodendrocyte pathology in AD can be regarded as a novel therapeutic target.Methods To address these questions, we subjected APP/PS1 transgenic mice and nontransgenic littermates to fluoxetine interventions for 2 months. After intervention, the behaviors were assessed with open field test and Morris water maze test, the changes in hippocampal oligodendrocytes were studied using immunohistochemistry, immunofluorescence, unbiased stereological techniques, laser scanning confocal microscope and molecular biotechnology.Results AD mice had an abnormally high number of oligodendrocyte lineage cells (Olig2 + cells) but lower expressions of CNPase and MBP and fewer mature oligodendrocytes (CNPase + cells) in the hippocampus than nontransgenic littermates. Among the oligodendrocyte lineage cells in the hippocampus of AD mice, fewer were mature oligodendrocytes and more were immature oligodendrocytes. Furthermore, decreased expression of SOX10, increased expression of LINGO1 and its ligands, and increased expression and activity of GSK3β might work together to induce oligodendrocyte maturation disorder in the hippocampus of AD mice. Fluoxetine treatment not only delayed the deficiencies in spatial learning and memory ability but also rescued the decrease in mature oligodendrocytes and reversed the abnormal increase in oligodendrocyte lineage cells in the hippocampus of AD mice, potentially by inhibiting the expression of LINGO1 and its ligands, inhibiting the expression and activity of GSK3β, reducing the levels of soluble Aβ40 and Aβ42, reducing β-amyloid plaques, reducing the ratio of oligodendrocytes expressing p16, promoting the expression of SOX10 in oligodendrocytes and promoting the maturation of newborn oligodendrocytes, and then increasing the number of mature oligodendrocytes in the hippocampus of AD mice.Conclusion There is oligodendrocyte maturation disorder in the hippocampus during early AD mice. Fluoxetine exposure during early AD may delay cognitive dysfunction by affecting hippocampal oligodendrocyte generation and maturation. Early hippocampal oligodendrocyte generation and maturation in AD might be regarded as a novel therapeutic target.

Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice

Fluoxetine Delays the Cognitive Function Decline and Synaptic Changes in a Transgenic Mouse Model of Early Alzheimer's Disease.

Fluoxetine Promotes Hippocampal Oligodendrocyte Maturation and Delays Learning and Memory Decline in APP/PS1 Mice

The Role of Fluoxetine in Activating Wnt/β-Catenin Signaling and Repressing β-Amyloid Production in an Alzheimer Mouse Model

Ganoderma Lucidum Triterpenoids (glts) Reduce Neuronal Apoptosis Via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice

Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice

Oligodendrocyte generation and maturation in the hippocampus may be a target of fluoxetine for delaying cognitive dysfunction during early Alzheimer’s disease

Emerging Therapeutic Potential of Fluoxetine on Cognitive Decline in Alzheimer's Disease: Systematic Review

Citalopram Restores Short-Term Memory Deficit and Non-Cognitive Behaviors in APP/PS1 Mice While Halting the Advance of Alzheimer's Disease-Like Pathology

Fluoxetine Mitigating Late-Stage Cognition and Neurobehavior Impairment Induced by Cerebral Ischemia Reperfusion Injury Through Inhibiting ERS-mediated Neurons Apoptosis in the Hippocampus

Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period.

Paroxetine Ameliorates Prodromal Emotional Dysfunction and Late-Onset Memory Deficit in Alzheimer’s Disease Mice

Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats

Fluoxetine induces input-specific hippocampal dendritic spine remodeling along the septotemporal axis in adulthood and middle age

Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice.

Albiflorin Ameliorates Memory Deficits in APP/PS1 Transgenic Mice Via Ameliorating Mitochondrial Dysfunction

Effect of FSD-C10 on modulation of inflammatory microenvironment in an Alzheimer disease double transgenic mouse model

Electroacupuncture Alleviates Memory Deficits in APP/PS1 Mice by Targeting Serotonergic Neurons in Dorsal Raphe Nucleus

AVP(4-8) Improves Cognitive Behaviors and Hippocampal Synaptic Plasticity in the APP/PS1 Mouse Model of Alzheimer’s Disease

Quercetin Attenuates Oxidative Stress and Apoptosis in Brain Tissue of APP/PS1 Double Transgenic AD Mice by Regulating Keap1/Nrf2/HO-1 Pathway to Improve Cognitive Impairment

3,6'-Disinapoyl sucrose alleviates cognitive deficits in APP/PS1 transgenic mice